Published in Clin Cancer Res on December 22, 2009
A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. Cancer Cell (2015) 1.77
Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res (2010) 1.38
Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer. Clin Cancer Res (2011) 1.03
Mixed lineage kinase 3 is required for matrix metalloproteinase expression and invasion in ovarian cancer cells. Exp Cell Res (2012) 0.97
Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway. PLoS One (2014) 0.93
JNK is a novel regulator of intercellular adhesion. Tissue Barriers (2013) 0.90
Overexpressed DNA polymerase iota regulated by JNK/c-Jun contributes to hypermutagenesis in bladder cancer. PLoS One (2013) 0.86
Dickkopf-1 is frequently overexpressed in ovarian serous carcinoma and involved in tumor invasion. Clin Exp Metastasis (2011) 0.84
Dab2 inhibits the cholesterol-dependent activation of JNK by TGF-β. Mol Biol Cell (2014) 0.83
Delivery strategies and potential targets for siRNA in major cancer types. Adv Drug Deliv Rev (2016) 0.82
The prognostic significance of Jun transcription factors in ovarian cancer. J Cancer Res Clin Oncol (2013) 0.82
A systems biology approach to the global analysis of transcription factors in colorectal cancer. BMC Cancer (2012) 0.80
Loss of tyrosine phosphatase-dependent inhibition promotes activation of tyrosine kinase c-Src in detached pancreatic cells. Mol Carcinog (2010) 0.78
Targeting c-MYC in Platinum-Resistant Ovarian Cancer. Mol Cancer Ther (2015) 0.78
Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents. Clin Cancer Res (2015) 0.77
Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival. Mol Clin Oncol (2016) 0.75
Inhibitory effect of black tea pigments, theaflavin‑3/3'-gallate against cisplatin-resistant ovarian cancer cells by inducing apoptosis and G1 cell cycle arrest. Int J Oncol (2017) 0.75
Mammalian MAP kinase signalling cascades. Nature (2001) 18.89
Signal transduction by the JNK group of MAP kinases. Cell (2000) 18.24
Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev (2001) 13.15
A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol (2005) 12.22
The stress-activated protein kinase subfamily of c-Jun kinases. Nature (1994) 11.45
Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev (1993) 10.01
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development. Curr Opin Cell Biol (1998) 6.28
The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron (1999) 4.51
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 4.24
Features of selective kinase inhibitors. Chem Biol (2005) 4.07
Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell (2004) 3.94
Non-parametric quantification of protein lysate arrays. Bioinformatics (2007) 3.18
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst (2002) 2.75
JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development. Curr Biol (1999) 2.60
Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2. Mech Dev (1999) 2.56
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell (2007) 2.43
Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst (1991) 2.33
Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res (2007) 2.28
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res (2009) 2.10
Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem (1991) 1.98
Signalling for survival and death in neurones: the role of stress-activated kinases, JNK and p38. Cell Signal (2001) 1.50
The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem (1997) 1.39
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest (2007) 1.34
Inhibition of cell proliferation and cell cycle progression by specific inhibition of basal JNK activity: evidence that mitotic Bcl-2 phosphorylation is JNK-independent. J Biol Chem (2004) 1.33
Inhibition of c-Jun N-terminal kinase 2 expression suppresses growth and induces apoptosis of human tumor cells in a p53-dependent manner. Mol Cell Biol (2000) 1.29
The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther (2006) 1.26
Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol Oncol (2004) 1.23
c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice. Cancer Res (2008) 1.23
The JUN kinase/stress-activated protein kinase pathway is required for epidermal growth factor stimulation of growth of human A549 lung carcinoma cells. J Biol Chem (1997) 1.15
c-Jun N-terminal kinase is essential for growth of human T98G glioblastoma cells. J Biol Chem (2000) 1.10
The c-Jun N-terminal kinase JNK functions upstream of Aurora B to promote entry into mitosis. Cell Cycle (2008) 1.09
Molecularly targeted therapy: have the floodgates opened? Oncologist (2004) 1.08
JNK supports survival in melanoma cells by controlling cell cycle arrest and apoptosis. Pigment Cell Melanoma Res (2008) 1.04
Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu Rev Pharmacol Toxicol (2005) 1.01
Inhibition of tumor growth, angiogenesis, and tumor cell proliferation by a small molecule inhibitor of c-Jun N-terminal kinase. J Pharmacol Exp Ther (2004) 1.00
Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy. Gynecol Oncol (2001) 0.92
Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity. Am J Clin Oncol (2004) 0.91
Inhibition of Jun NH2-terminal kinases suppresses the growth of experimental head and neck squamous cell carcinoma. Clin Cancer Res (2007) 0.89
Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target. Cancer Res (2007) 0.88
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA (2011) 6.81
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med (2006) 6.18
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med (2011) 6.15
MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol (2011) 5.46
Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell (2003) 5.44
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest (2007) 5.17
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol (2005) 4.77
The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer (2006) 4.27
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 4.24
Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol (2008) 3.68
Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet (2003) 3.61
Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med (2012) 3.54
RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43
The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res (2010) 3.36
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics (2010) 3.25
Non-parametric quantification of protein lysate arrays. Bioinformatics (2007) 3.18
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging (2004) 3.07
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol (2011) 2.90
Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med (2004) 2.89
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest (2009) 2.80
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol (2013) 2.69
Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol (2011) 2.64
Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy (2010) 2.62
Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res (2003) 2.50
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res (2005) 2.48
Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer (2003) 2.48
Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med (2005) 2.43
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst (2008) 2.40
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst (2008) 2.37
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell (2013) 2.34
Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res (2007) 2.32
Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res (2006) 2.32
Computational identification of gene-social environment interaction at the human IL6 locus. Proc Natl Acad Sci U S A (2010) 2.31
Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res (2007) 2.28
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther (2010) 2.27
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res (2010) 2.19
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res (2008) 2.17
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest (2010) 2.04
Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res (2007) 1.98
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Platelets increase the proliferation of ovarian cancer cells. Blood (2012) 1.97
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol (2010) 1.95
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol (2006) 1.93
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res (2007) 1.90
A novel platform for detection of CK+ and CK- CTCs. Cancer Discov (2011) 1.88
Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res (2008) 1.88